{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:57:26Z","timestamp":1778777846431,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":166,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.prdoa.2020.100063","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T20:47:57Z","timestamp":1592254077000},"page":"100063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice"],"prefix":"10.1016","volume":"3","author":[{"given":"Richard M.","family":"Trosch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay P.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savary","family":"Om","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.prdoa.2020.100063_bb0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2020.100063_bb0010","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","article-title":"Treatment of dystonia","volume":"5","author":"Jankovic","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prdoa.2020.100063_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport German Dystonia Study Group","volume":"64","author":"Poewe","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.prdoa.2020.100063_bb0020","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s004150170028","volume":"248","author":"Wissel","year":"2001","journal-title":"J. Neurol."},{"key":"10.1016\/j.prdoa.2020.100063_bb0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2020.100063_bb0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2020.100063_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2020.100063_bb0040","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/mds.26760","article-title":"Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial","volume":"31","author":"Poewe","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2020.100063_bb0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","article-title":"Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review","volume":"22","author":"Colosimo","year":"2012","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.prdoa.2020.100063_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2020.100063_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40734-018-0072-8","article-title":"Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies","volume":"5","author":"Misra","year":"2018","journal-title":"J Clin Mov Disord"},{"key":"10.1016\/j.prdoa.2020.100063_bb0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2017.02.042","article-title":"Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: the ANCHOR-CD registry","volume":"376","author":"Trosch","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.prdoa.2020.100063_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-000881","article-title":"Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study","volume":"2","author":"Misra","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.prdoa.2020.100063_bb0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00415-017-8698-2","article-title":"INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin","volume":"265","author":"Misra","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.prdoa.2020.100063_bb0075","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1007\/s00415-019-09527-2","article-title":"How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study","volume":"266","author":"Colosimo","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.prdoa.2020.100063_bb0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.parkreldis.2018.03.002","article-title":"Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale","volume":"52","author":"Espay","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2020.100063_bb0085","doi-asserted-by":"crossref","first-page":"116413","DOI":"10.1016\/j.jns.2019.07.031","article-title":"Minimal clinically important change in patients with cervical dystonia: results from the CD PROBE study","volume":"405","author":"Dashtipour","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.prdoa.2020.100063_bb0090","unstructured":"Dysport (abobotulinumtoxinA) for Injection, for Intramuscular Use. Full US Prescribing Information 2019. Available at http:\/\/dysport.com. Last accessed May 2020."},{"key":"10.1016\/j.prdoa.2020.100063_bb0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","article-title":"Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE)","volume":"349","author":"Jankovic","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.prdoa.2020.100063_bb0100","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"S1","key":"10.1016\/j.prdoa.2020.100063_bb0105","first-page":"S110","article-title":"Time to retreatment with botulinum toxin A in upper limb spasticity management: upper limb international spasticity (ULIS)-III study interim analysis","volume":"156","author":"Turner-Stokes","year":"2019","journal-title":"Toxicon"},{"key":"10.1016\/j.prdoa.2020.100063_bb0110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/toxins10120535","article-title":"AbobotulinumtoxinA (Dysport), OnabotulinumtoxinA (Botox), and IncobotulinumtoxinA (Xeomin) neurotoxin content and potential implications for duration of response in patients","volume":"10","author":"Field","year":"2018","journal-title":"Toxins (Basel)"},{"issue":"Suppl. 1","key":"10.1016\/j.prdoa.2020.100063_bb0115","article-title":"How do patients with cervical dystonia (CD) experience their botulinum neurotoxinA (BoNT-A) treatment cycle: results from an international online survey","volume":"27","author":"Ferreira","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2020.100063_bb0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.prdoa.2020.100063_bb0125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.toxicon.2018.01.018","article-title":"Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - insights from recent studies","volume":"147","author":"Wissel","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.prdoa.2020.100063_bb0130","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1212\/WNL.94.15_supplement.998","article-title":"Impact of injection schedule flexibility on patient satisfaction with botulinum toxin treatment for cervical dystonia","volume":"94","author":"Misra","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2020.100063_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-1331.2004.01053.x","article-title":"The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment","volume":"12","author":"Skogseid","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2020.100063_bb0140","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00702-012-0887-7","article-title":"Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy","volume":"120","author":"Jost","year":"2013","journal-title":"J. Neural Transm."},{"issue":"Suppl. 2","key":"10.1016\/j.prdoa.2020.100063_bb0145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1468-1331.2010.03130.x","article-title":"Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement","volume":"17","author":"Novak","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2020.100063_bb0150","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.3390\/toxins7062321","article-title":"Pain relief in cervical dystonia with botulinum toxin treatment","volume":"7","author":"Camargo","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.prdoa.2020.100063_bb0155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0304-3959(96)03153-3","article-title":"Pain perception in idiopathic cervical dystonia (spasmodic torticollis)","volume":"67","author":"Lobbezoo","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.prdoa.2020.100063_bb0160","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00702-020-02163-5","article-title":"Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study","volume":"127","author":"Siongco","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.prdoa.2020.100063_bb0165","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/papr.12408","article-title":"Neck pain and cervical dystonia: treatment outcomes from CD PROBE (cervical dystonia patient registry for observation of OnabotulinumtoxinA efficacy)","volume":"16","author":"Charles","year":"2016","journal-title":"Pain Pract"},{"key":"10.1016\/j.prdoa.2020.100063_bb0170","article-title":"Prospective study evaluating IncobotulinumtoxinA for cervical dystonia or blepharospasm: interim results from the first 145 subjects with cervical dystonia","volume":"3","author":"Fernandez","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.prdoa.2020.100063_bb0175","doi-asserted-by":"crossref","unstructured":"Albanese A, Abbruzzese G, Dressler D, Duzynski W, Khatkova S, Marti MJ, Mir P, Montecucco C, Moro E, Pinter M, Relja M, Roze E, Skogseid IM, Timerbaeva S, Tzoulis C (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J. Neurol. 262, 3301\u20132213.","DOI":"10.1007\/s00415-015-7703-x"}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112520300311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112520300311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:48:40Z","timestamp":1762912120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112520300311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":35,"alternative-id":["S2590112520300311"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2020.100063","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2020.100063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100063"}}